---
title: "Weight loss new drug falls short of expectations, Novo Nordisk plummets nearly 30% in pre-market! Competitor Eli Lilly surges over 10%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/222920984.md"
description: "Novo Nordisk stated on Friday that its next-generation obesity drug Cagrisema achieved only a 22.7% weight loss in a trial, below its expected 25%"
datetime: "2024-12-20T11:07:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/222920984.md)
  - [en](https://longbridge.com/en/news/222920984.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/222920984.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/222920984.md) | [繁體中文](https://longbridge.com/zh-HK/news/222920984.md)


# Weight loss new drug falls short of expectations, Novo Nordisk plummets nearly 30% in pre-market! Competitor Eli Lilly surges over 10%

A highly anticipated study shows that a dual-drug combination called CagriSema helped people lose an average of 22.7% of their weight after more than a year of weekly injections, while patients receiving a placebo lost 2.3%.

Novo Nordisk stated on Friday that its experimental next-generation obesity drug CagriSema helped overweight patients lose 22.7% of their weight in a late-stage trial, falling short of its expected 25%, leading to a significant drop in its stock price.

Meanwhile, competitor Eli Lilly surged over 9% in pre-market trading after Novo Nordisk released the clinical data for CagriSema, which showed that patients lost 22.7% of their weight in the trial, below previous expectations

### Related Stocks

- [Novo Nordisk A/S (NVO.US)](https://longbridge.com/en/quote/NVO.US.md)
- [Eli Lilly and Company (LLY.US)](https://longbridge.com/en/quote/LLY.US.md)

## Related News & Research

- [UK Regulator Recommends Novo Nordisk's Wegovy for People at Risk of Heart Attacks, Strokes](https://longbridge.com/en/news/281294814.md)
- [Novo Nordisk slashes Wegovy prices to court uninsured patients](https://longbridge.com/en/news/281206892.md)
- [Novo Nordisk Launches Discounted Subscription Program for Wegovy Obesity Drugs -- Update](https://longbridge.com/en/news/281201382.md)
- [Novo Nordisk A/S Approves Final Dividend for 2025, Payable in March 2026](https://longbridge.com/en/news/280694679.md)
- [Novo Nordisk cuts Ozempic and Wegovy prices by up to 48% in India](https://longbridge.com/en/news/281167899.md)